Peroxisome proliferators, such as lipid-lowering fibrate drugs, are agonists for the peroxisome proliferatoractivated receptor a (PPARa). Sustained activation of PPARa leads to the development of liver tumors in rodents. Paradoxically, humans appear to be resistant to the induction of peroxisome proliferation and development of liver tumors by peroxisome proliferators. To examine the species differences in response to peroxisome proliferators, a PPARa humanized mouse (hPPARa) was generated, in which the human PPARa was expressed in liver under control of the Tet-OFF system. To evaluate the susceptibility of hPPARa mice to peroxisome proliferatorinduced hepatocarcinogenesis, a long-term feeding study of Wy-14,643 was carried out. hPPARa and wild-type (mPPARa) mice were fed either a control diet or one containing 0.1% Wy-14,643 for 44 and 38 weeks, respectively. Gene expression analysis for peroxisomal and mitochondrial fatty acid metabolizing enzymes revealed that both hPPARa and mPPARa were functional. However,
Introduction
A variety of chemicals such as hypolipidemic drugs, phthalate ester plasticizers and industrial solvents have been shown to increase the size and number of peroxisomes in rats and mice (1) . Because of their unique property of inducing peroxisome proliferation, they are grouped as peroxisome proliferators (2) . The hepatic changes caused by treatment with peroxisome proliferators include liver hyperplasia and hypertrophy, proliferation of peroxisomes, and increases in the oxidation of fatty acids through induction of genes encoding mitochondrial, peroxisomal and microsomal enzymes involved in fatty acid oxidation (3, 4) . Long-term treatment of mice and rats with peroxisome proliferators eventually results in the formation of hepatocellular adenomas and/or carcinomas; these chemicals are regarded as non-genotoxic carcinogens since they do not directly cause genetic damage (5) (6) (7) (8) (9) .
Peroxisome proliferators exert their effects by activating peroxisome proliferator-activated receptor a (PPARa), a member of the superfamily of ligand-activated, nuclear receptors. In response to ligand activation of PPARa, there is an increase in expression of target genes encoding enzymes and proteins involved in fatty acid transport and catabolism (3). In rodent model systems, PPARa has also been implicated in regulating a number of other biological processes including cell proliferation, apoptosis, inflammation and oxidative stress. Targeted disruption of the mouse Ppara gene confirmed that this receptor is responsible for the peroxisome proliferator-induced pleiotropic responses in mice including the process of hepatocarcinogenesis (5, 10) . Notable species differences in response to peroxisome proliferators have been demonstrated (11, 12) . In spite of their carcinogenic activity in mice and rats, primate and humans appear to be resistant to the induction of peroxisome proliferation and the development of hepatocarcinomas after chronic exposure to the peroxisome proliferator fibrate drugs (13) (14) (15) . However, humans treated with gemfibrozil, a hypolipidemic drugs, for many years have shown no evidence for increased peroxisomes or other pathological alterations found in rodents (14) . In addition, epidemiological studies on hypolipidemic drugs showed no increase in cancer incidence (16) . Although human PPARa was shown to be functional in transactivation assays (17) (18) (19) , the mechanism underlying the species difference in response to peroxisome proliferators is still unknown.
Recently, a novel transgenic mouse line humanized for PPARa (hPPARa mice) was generated in order to elucidate the mechanism of species difference in response to peroxisome proliferators (20) . These mice express human PPARa specifically in the liver under the control of the doxycycline (Tet-OFF) system in a PPARa null background. When treated for up to 8 weeks with the potent peroxisome proliferator, [4-chloro-6-(2,3-xylidino)-pyrimidynylthio]acetic acid (Wy-14,643), hPPARa mice exhibit decreased serum triglycerides and increased expression of genes encoding peroxisomal, mitochondrial and microsomal fatty acid oxidation enzymes, albeit to a lesser extent than wild-type mice. However, unlike wild-type mice, the hPPARa mice did not display increases in ligand-induced hepatomegally, cell proliferation and expression of cell cycle control genes. These data suggest that the hPPARa mouse may be resistant to peroxisome proliferator-induced hepatocarcinogenesis.
In the present study, to determine the susceptibility of the hPPARa mice to peroxisome proliferators-induced hepatocarcinogenesis, a long-term feeding study of Wy-14,643 was carried out. Expression of some direct PPARa target genes involved in the regulation of the cell cycle was also analyzed.
Materials and methods

Animals and treatments
A mouse line humanized for the hPPARa was generated as previously described (20) . Briefly, a tetracycline response element (TRE) driving human PPARa cDNA transgene (TRE-hPPARA) was microinjected into fertilized FVB/N mouse eggs, and transgene-positive mice were mated to mice expressing the tetracycline-controlled transactivator (tTA) transgene, under the control of the liver-specific Cebp/b promoter (tTALap5Bjd), (21) . Mice expressing both transgenes were bred into a mouse PPARa-null background (129/S4/SvJae-Ppara tm1Gonz/J ) to generate CEBP/b-tTA; TRE-hPPARa; PPARa-null transgenic mice (129S4/SvJae.Cg-Ppara tm1Gonz/J Tg(TREhPPARA)1Gonz Tg(tTALap)5Bjd). This mouse line expresses human PPARa cDNA in the liver hepatocytes on a mouse PPARa-null background in the absence of doxycycline, a tetracycline derivative (Tet-OFF system). The genotypes for all animals used in this study were verified using PCR detection of tTA (tTA forward, 5 0 -CTCGCCCAGAAGCTAGGTGT-3 0 ; tTA reverse,
0 ; and maNEOR1, 5 0 -GCAATC-CATCTTGTTCAATGGC-3 0 , recognizing wild-type allele at $400 bp and the null allele at $650 bp), and human PPARa (hPPAR2 GENO F3, 5 0 -CGATTTCACAAGTGCCTTTCTGTC-3 0 ; hPPAR2 GENO R3, 5 0 -AAGTTTGCGAAGCCTGGGATGG-3 0 , recognizing at 430 bp). A total of 30, 6-week-old male hPPARa mice were divided into two groups and 10 and 20 mice were given a pelleted diet with or without 0.1% (w/w) Wy-14,643 (ChemSyn Science Laboratories, Lenexa, KS, USA) up to week 44 of the experimental period, respectively. Similarly, a total of 19, 6-week-old male wild-type mice (mPPARa mice) with the same background were divided into two groups, and 9 and 10 animals were given diet with or without Wy-14,643 until the final killing at week 38 of the experimental period, respectively. Animals were housed 4-5 in plastic cages with hard wood chips for bedding in an animal room with a 12 h light/dark cycle, carefully monitored general health status, and the body weights were measured weekly until week 5, after which weights were measured once every two weeks. Those becoming moribund during the course of the study were killed by CO 2 asphyxiation and examined histologically before the termination of the experiment. All animal experimental procedures were carried out in accordance with animal study protocols approved by the National Cancer Institute Animal Care and Use Committee.
Histological analysis
Mice were killed at the termination of the experiment and liver tissues were carefully investigated for the existence of tumors after being weighed, and small portions of liver tissues without any macroscopic nodules were snap frozen in liquid nitrogen and stored at À80
C until further analysis. The remaining liver tissues were fixed in 10% phosphate-buffered formalin, embedded in paraffin, sectioned at 3-4 mM, and prepared for routine hematoxylin and eosin staining for histological examination. The lesions and tumors found were classified according to the criteria of the International Agency for Research on Cancer (WHO) (22) .
Western blot analysis
Nuclear extracts from liver samples were prepared using NE-PER nuclear extraction kit (Pierce Chemical, Rockford, IL, USA), separated on 10% SDS-PAGE and blotted onto nitrocellulose membrane (Whatman, Stanford, ME, USA). The membrane was incubated overnight at 4 C with a 1:750 dilution of a primary antibody against PPARa (Geneka Biotechnology, Montreal, Canada) and GAPDH (Chemicon International, Temecula, CA, USA).
After washing, the membrane was incubated for 30 min with 1:10 000-diluted horseradish peroxidase-conjugated secondary antibodies (Sigma, St Louis, MO, USA), and the reaction product was visualized using SuperSignal West Pico an enhanced Chemiluminescent Substrate (Pierce).
Northern blot analysis
Total RNA was extracted from liver using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). Northern blot analysis was carried out as described previously (23) and hybridized with random primer 32 P-labeled cDNA probes (23, 24) , and exposed to a PhosphorImager screen cassette followed by visualization using a Storm 860 PhosphorImager system (Amersham Biosciences, NJ, USA). Signals were quantified using ImageQuant TL software (Amersham Biosciences). The expression levels of target genes were normalized with those of reference gene (acidic ribosomal phosphoprotein; 36B4). Five mice each per group were subjected to the analysis.
Statistical analysis
Survival curves were created using the Kaplan-Meier method, and the statistical significance of differences was calculated by the log-rank test. Variations in liver/body weight ratio, incidences of tumors, gene expression analysis between the different treatments or animal strains were evaluated with oneway fractorial ANOVA and multiple comparison tests. All the calculations for statistical analysis were performed using the Statview SE+ Graphics, version 5.0 (Abacus Concepts, Berkeley, CA, USA).
Results
Survival, body and liver weights
From the onset of the experiment, Wy-14,643-treated mPPARa mice exhibited suppressed growth compared with all other groups and the percentage of animals of this group that survived decreased to 50% at the termination of the study period (Figures 1 and 2 ). Of the 10 mice in the Wy-14,643-treated mPPARa group, 3 died of toxicity and were not evaluated further whereas 2 mice were killed due to morbidity before the termination of the experiment. However, the Wy-14,643-treated hPPARa mice showed a similar rate of growth as those of the non-treated control mice of both strains, and only one animal in this group was killed due to morbidity before termination of the experiment (Figures 1 and 2) .
The final body weight of Wy-14,643-treated mPPARa mice was markedly decreased and both absolute and relative liver weights increased as compared with those of all other groups (Table I) . Wy-14,643-treated hPPARa mice showed an increased absolute and relative liver weights compared with the corresponding control diet group; however, the extent of increase was considerably less that found in the Wy-14,643-treated mPPARa mice (Table I) . 
Hepatocarcinogenicity in PPARa-humanized mice
Hepatic lesions
Most of the mPPARa mice fed the Wy-14,643 diet had multiple, grossly visible nodules that were randomly distributed among the liver lobes ( Figure 3A) . The hepatocellular adenomas were well-circumscribed lesions compressing adjacent parenchyma without normal lobular architecture, and were composed of well-differentiated hepatocytes ( Figure 3E ). The hepatocellular carcinomas were characterized by a trabecular or pseudoglandular histologic pattern ( Figure 3F) . Table II shows incidence of the hepatocellular adenoma/ carcinoma and pre-neoplastic altered cell foci in the liver of the various groups. The incidence of hepatocellular adenomas in the Wy-14,643-treated mPPARa mice was 71% and two animals had hepatocellular carcinomas. Most animals in this group with tumors had single or multiple altered cell foci ( Figure 3B and C) . In contrast, only 1 out of 20 hPPARa mice treated with Wy-14,643 harbored a hepatocellular adenoma, and significant differences in the incidence was detected as compared with Wy-14,643-treated mPPARa mice. This tumor was also morphologically similar to spontaneous mouse liver tumor with basophilic and clear hepatocytes, whereas the tumors in mPPARa mice were more diffusely basophilic. Altered cell foci were detected in one hPPARa animal in each of the mice with and without Wy-14,643 treatment. Histologically, toxic lesions induced by Wy-14,643 were seen in mPPARa mice and were much less severe in hPPARa mice (Figure 3B-D) .
PPARa expression
At the termination of the carcinogenicity study, both gene and protein expression levels of PPARa were evaluated using the non-tumorous portion of liver tissue (Figure 4) . Total RNAs were hybridized with specific probes for human and mouse PPARa genes independently for northern blot analysis. Both hPPARa and mPPARa mice showed expression of the respective human and mouse PPARa mRNA regardless the treatment Fig. 2 . Time-course changes in survival rates. Mice were examined twice a week and those exhibiting distress were killed. Surviving curves were created using the Kaplan-Meier method.
Ã P < 0.05 versus all other groups (log-rank test). Includes liver from mice that were euthanized due to morbidity before the termination of experiment. of Wy-14,643 ( Figure 4A ). Moreover, PPARa proteins were also expressed similarly in hPPARa and mPPARa mice ( Figure 4B ).
Gene expression analysis
To examine the expression of PPARa target genes and genes involved in cell cycle/apoptosis, northern blot analyses were carried out ( Figure 5A ), using non-tumorous portions of liver collected at the termination of the animal experiment, and quantification of expression normalized with a reference gene ( Figure 5B-D) . Expression levels of acyl-CoA oxidase (ACOX), cytochrome P450 A (CYP4A) and medium chain acyl-CoA dehydrogenase (MCAD) mRNAs in both Wy-14,643-treated hPPARa and mPPARa mice were significantly increased, compared with those of corresponding groups fed the control diet ( Figure 5B ). mRNA encoding malic enzyme (ME) was significantly increased in the Wy-14,643-treated mPPARa group, compared with that of the control diet group, but no difference was detected between Wy-14,643-and control-diet-treated hPPARa mice groups. Figure 5C shows the expression level of genes regulating cell cycles. mRNAs encoding CD1, cyclin-dependent kinases (CDKs) 1 and 4 were highly expressed in the livers of the Wy-14,643-treated mPPARa mouse group and were statistically different from those in all other groups. The cMYC mRNA was also significantly overexpressed in the Wy-14,643-treated mPPARa group compared with those of control-diet-treated mPPARa group, but no difference was detected compared with those of other groups. The mRNAs encoding apoptosis associated proteins, p53, p21, BAX and BCL2 were also examined ( Figure 5D ). Expression of the p53 gene was increased in the Wy-14,643-treated hPPARa group as compared with those of all other groups, although the P-value between Wy-14,643-treated mPPARa was marginal (P ¼ 0.416). The p21 mRNA showed a slight but not statistically significant increase in the Wy-14,643-treated hPPARa. No difference was found in expression of mRNAs encoding BAX and BCL2 among all groups.
Discussion
Chronic dietary exposure of mice and rats to Wy-14,643 and other peroxisome proliferators typically results in hepatocellular neoplasia (5, (7) (8) (9) . In the present study, a high incidence of hepatocellular tumors (71%) including hepatocellular carcinomas was detected in mPPARa, fed with 0.1% Wy-14,643 for up to 38 weeks. Owing to the moribund status of mice in this group, Wy-14,643 treatment was prematurely terminated at 38 weeks from the beginning of the experiment. In sharp contrast, hPPARa mice given the same diet for up to 44 weeks, at which the wild-type mice exhibited a 100% incidence of liver tumors under the same treatment (5), demonstrated a very low incidence of hepatocellular tumors (5%). This observation represents conclusive evidence for low-susceptibility of this humanized mouse model to peroxisome proliferator-induced hepatocarcinogenesis.
In the presence of ligand, PPARa heterodimerizes with RXRa and binds to peroxisome proliferator response elements (PPREs) in the promoter region of target genes, resulting in increased transcription and expression of proteins and enzymes necessary for the transport and catabolism of fatty acids. A large number of genes including peroxisomal (Acox), microsomal (Cyp4a) and mitochondrial (Mcad) fatty acid oxidation genes, as well as fatty acid synthase (Fas) gene are well documented as PPARa target genes (25) . In this study, the expression of most of these target genes were elevated in the Wy-14,643-treated hPPARa mouse, revealing that hPPARa was functional in control of fatty acid homeostasis similar to the wild-type mouse and that transcription was continuously stimulated throughout the course of ligand treatment.
Cyclins and CDKs regulate the cell cycle and overexpression of these proteins can results in uncontrolled cell proliferation. These proteins were previously found to be markedly upregulated in wild-type mice fed Wy-14,643 (26) . Consistent with these findings, a number of cell cycle control genes were also upregulated in the mPPARa mouse group fed Wy-14,643, whereas the hPPARa mouse, under the same treatment regimen, did not show increased expression of these genes. These results indicate that genes associated with cell proliferation are preferentially activated in the livers of wild-type mice as compared with the hPPARa mouse line or that the severe toxicity and/or hepatocyte damage in the wild-type mouse results in induction of cell cycle control genes associated with the hepatocyte regenerative response. However, whether an increase in the expression of these genes is a cause or an effect of carcinogenesis is not elucidated in this study, because the total RNAs used in this analysis were derived from liver tissues of mice chronically exposed to Wy-14,643.
In response to the ligand activation, a number of lipidmetabolizing enzymes are induced in rodents. Increased levels of enzymes associated with the peroxisomal fatty acid b-oxidation system including acyl-CoA oxidase and to a lesser degree, the microsomal CYP4A subfamily of enzymes involved in fatty acids w-oxidation leads to the generation of hydrogen peroxide (H 2 O 2 ) (27) . Increased H 2 O 2 could potentially react with metals and generate highly reactive hydroxyl radicals, or react with lipid resulting in lipid peroxides ultimately elevating reactive oxygen species (ROS) and the degree of oxidative stress that can cause damage to DNA, protein, lipids and other cellular components that contribute to hepatocarcinogenesis in rodents (28) . However, ROS may also act as a second intermediate in intracellular signaling (29) or inhibit the Hepatocarcinogenicity in PPARa-humanized mice mitochondria respiratory chain complex leading to apoptosis (30, 31) . Although suppression of apoptosis has been implicated as a mechanism for hepatocarcinogenicity of peroxisome proliferators, these compounds can induce cell death in the human HepG2 cell line (32) . A peroxisome proliferator, BR931, was also demonstrated to induce apoptosis through a p53-dependent pathway in the rat hepatoma FaO cell line (33) . Overexpression of the p53 gene in Wy-14,643-treated hPPARa mice may imply that a sustained activation of the programmed cell death system contributes to the resistance to hepatocarcinogenesis, in contrast to the Wy-14,643-treated mPPARa mice group with comparatively lower expression of the p53 gene. However, the mutated form of this protein is retained in the cell, resulting an abnormal cell cycle. Besides, it should be noted that hepatoma cells lines are markedly different from hepatocytes and thus the results obtained with a rat hepatoma FaO cell line may not reflect the activity of peroxisome proliferators in vivo. Additional studies are necessary to establish a role for p53 in the resistance of the hPPARa mice to hepatocarcinogenesis.
It must be considered that hepatic levels of PPARa and/or different ligand affinity of receptor could account for the differential response in cell proliferation between mice and humans as revealed in the altered expression of cell cycle control genes involved in hepatocyte proliferation and carcinogenesis. Indeed, transient retroviral overexpression of the human PPARa in PPARa-null mice resulted in induction of some target genes accompanied by increased cell proliferation, indicating the higher level of human PPARa may contribute liver cell proliferation (19) . A different ligand affinity for Wy-14,643 between human and mouse PPARa was also reported (34) . However, the level of PPARa expression does not appear to be critical in this model, because the cellular content of human PPARa protein in the hPPARa mice detected in this study was similar to the mouse PPARa protein levels in wild-type mice. Furthermore, similar expression levels of several potent PPARa target genes such as ACOX and CYP4A were found comparing the wild-type and PPARa mice, indicating that the ligand affinity differences between human and mouse PPARa may not be important under the conditions used in these experiments. It also cannot be ruled out that the hPPARa mice are resistant to the hepatotoxic effects of peroxisome proliferators due to the site of expression of the human receptor. The cDNA was placed under control of the tetracycline regulatory system and the liver-specific Cebp/b promoter that is preferentially expressed in hepatocytes. Thus, it cannot be excluded that expression of PPARa in other cells in the liver such as Kupffer or stellate cells may be involved in the hepatoproliferative response. However, PPARa is not expressed at appreciable levels in Kupffer cells (35) .
The rodent model is widely accepted as a useful tool for evaluating chemical carcinogenicity and/or toxicity, in accordance with the recommendation of the International Conference on Harmonization of Technical Requirements of Pharmaceuticals for Human Use (ICH). However, for assessment of the hazards of peroxisome proliferators, including hypolipidemic drugs, to human health, an explanation for the interspecies differences to those chemicals yields some important insights. Although the epidemiological studies on long-term treatment with hypolipidemic drugs showed inconclusive evidence of carcinogenic effects in humans (16) , elucidation of the mechanisms by which peroxisome proliferators induce carcinogenesis is a prerequisite to accurately assess the human risk. In this regard, the hPPARa mouse model will provide a valuable model for determining the mechanism of the species differences in liver carcinogenesis and the mechanism of action of non-genotoxic hepatocarcinogens.
